Likewise, SPRY4 suppression occurs in hepatocellular carcinoma drug-resistant patients, where histone deacetylase 4 (HDAC4) modifies the histone configuration within the SPRY4 promoter region, resulting in a heterochromatin (silenced) state [26]. Here, HDAC4 is linked to hepatocellular carcinoma.